PMV Pharmaceuticals Inc (PMVP) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy...

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in...

PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial

Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as...

Form 4 - Statement of changes in beneficial ownership of securities